Symbio Research
Shrutimita Pokhariyal is a Principal Statistician at Symbio Proinnovera, specializing in Phase 2, 3, and 4 studies within the Dermatology and Aesthetics domains since October 2022. Prior experience includes serving as Principal Biostatistician at ClinChoice, where responsibilities involved preparing statistical analysis plans and reviewing SAPs, and as a Senior Biostatistician at Syneos Health, focusing on Phase 3 and 4 Dermatology and Consumer Health projects. Earlier roles include Biostatistician positions at GCE Solutions Inc. and Max Neeman International, as well as Statistician II at Quanticate, where work encompassed sample size calculations, dataset validation, and statistical analysis plan development. Shrutimita holds a Master of Science in Biostatistics and a Bachelor of Science in Public Health, both from The Maharaja Sayajirao University of Baroda.
This person is not in any offices
Symbio Research
Headquartered in Port Jefferson, NY, Symbio is a client-focused global full service Clinical Research Organization (CRO). We manage all CRO core services in house and have our offices in the USA and Europe. We deliver excellent service and provide experienced qualified personnel to strategically manage all aspects of your clinical trials. Symbio offers expertise in Proof-of-Concept, medical device and Phase I – Phase IV clinical studies and has completed over 115 clinical studies to date, both in the USA and in other territories. Developing and maintaining excellent relationships with experienced clinical research sites are vital to the success of any study and every CRO. As a direct result of our site relationships, Symbio trials receive the special attention they deserve. We take great pride in the strong relationships we have established through the years. These relationships have provided us the ability to streamline recruitment, creating shorter enrollment timelines with a lower number of sites. Our expertise starts from the top. Symbio, LLC was founded in 2002 by Richard Panico and Debra Dow. With previous leadership roles in CRO management and product development, Rich and Deb have been able to successfully grow their company by carefully selecting qualified clinical research professionals. In collaboration with senior management, their continued oversight offers clients a personalized experience ensuring study management challenges are anticipated, identified and resolved quickly and efficiently. In 2018 Richard Panico, Debra Dow and Veronika Kunert founded Symbio’s subsidiary in Europe to support our clients with their global clinical trials. The vision from the start has been to create a CRO that consistently delivers outstanding service and quality to sponsors. The common goal is to bring clinical studies to a successful end, on time and on budget.